Fig. 2

The abundance of sSEZ6 and sgp130 in body fluids is dependent on BACE1 activity. a Western Blots of CSF sSEZ6 from participants of a clinical phase 1 study treated with placebo or 100 mg verubecestat (N = 6 per condition). A volume of 15 μL of CSF was loaded per lane. The baseline samples (0 h) and post-dose samples at 30 h are plotted next to each other. b The quantification of the relative abundance change of sSEZ6 shows an increase of more than two-fold in the placebo group, whereas the abundance was reduced to 54% in the 100 mg verubecestat group. c Relative abundance change of sgp130 in the same samples measured by ELISA (n = 6 per condition) shows an increase to 184% in the placebo group, whereas values decrease to 71% in the 100 mg verubecestat group. d-g The log2 transformed post-dose to pre-dose ratios of sSEZ6 and sgp130 correlate with those detected for Aβ42 and sAPPβ (extracted from [27]). h The levels of sgp130 detected by ELISA in the serum of BACE1−/− mice [59] show a decrease compared to the wildtype controls (N = 8 per condition). Shown are mean values ± SD. Unpaired Student t-tests were performed for the individual comparisons. ***: p < 0.001